Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 31, 2025 16:30 ET | Source: Edesa Biotech, Inc.

Edesa Biotech Announces Upcoming Conference Schedule

TORONTO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
October 28, 2025 07:45 ET | Source: Edesa Biotech, Inc.

Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study

Study met primary and secondary endpointsParidiprubart demonstrated a relative reduction in the risk of death of 25%Treatment provided patients with clinically meaningful improvement in survival and...
August 08, 2025 16:35 ET | Source: Edesa Biotech, Inc.

Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results

TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
May 14, 2025 16:15 ET | Source: Edesa Biotech, Inc.

Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results

Edesa Second Quarter Earnings Release 2025
April 28, 2025 16:30 ET | Source: Edesa Biotech, Inc.

Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference

TORONTO, April 28, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
April 04, 2025 16:15 ET | Source: Edesa Biotech, Inc.

Edesa Biotech Announces Chief Financial Officer Transition

TORONTO, April 04, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
February 14, 2025 16:15 ET | Source: Edesa Biotech, Inc.

Edesa Biotech Reports Fiscal 1st Quarter 2025 Results

TORONTO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
February 13, 2025 07:00 ET | Source: Edesa Biotech, Inc.

Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Financing led by Velan Capital with participation from new and existing healthcare-focused institutional investors and insidersCapital raise to fund Edesa’s CXCL10 antibody program through the end of...
December 13, 2024 16:30 ET | Source: Edesa Biotech, Inc.

Edesa Biotech Reports Fiscal Year 2024 Results

TORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
October 31, 2024 08:15 ET | Source: Edesa Biotech, Inc.

Edesa Biotech’s Founder Makes Strategic Investment in the Company

TORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...